Petrichor Capital Partners
Petrichor Capital Partners is a venture capital firm launched in 2018, dedicated to supporting world-class healthcare managers and businesses. The firm provides structured investments to foster the development and commercial growth of innovative biopharmaceuticals, medical technologies, and services. With a deep in-house understanding of scientific, technical, and commercial expertise, Petrichor aims to identify and support the next generation of healthcare innovation, spanning from company formation to late-stage growth opportunities.
Industries
N/A
Nr. of Employees
small (1-50)
Petrichor Capital Partners
220 East 42nd Street, 37th / PH Floor, New York, NY 10017
Portfolio
Scion Life Sciences is dedicated to founding and building exceptional biotechnology companies that discover, develop, and seek to commercialize clinically transformational or curative new medicines.
#Biotechnology
Fennec Pharmaceuticals has received multiple investments from Petrichor, including a $45 million investment and a $20 million investment. The company has also announced FDA approval for PEDMARK® (Sodium Thiosulfate Injection).
#Pharmaceuticals
ITM has been involved in multiple collaborations and agreements, including a supply agreement for Actinium-225 and the opening of the world's largest Lutetium-177 production facility.
#Radiopharmaceuticals
Aurion Biotech has raised $120 million from various investors, including Petrichor, and has received breakthrough therapy designation for its drug candidate AURN001.
#Biotechnology
Scion Life Sciences is dedicated to founding and building exceptional biotechnology companies that discover, develop, and seek to commercialize clinically transformational or curative new medicines.
#Biotechnology
Fennec Pharmaceuticals has received multiple investments from Petrichor, including a $45 million investment and a $20 million investment. The company has also announced FDA approval for PEDMARK® (Sodium Thiosulfate Injection).
#Pharmaceuticals
ITM has been involved in multiple collaborations and agreements, including a supply agreement for Actinium-225 and the opening of the world's largest Lutetium-177 production facility.
#Radiopharmaceuticals
Aurion Biotech has raised $120 million from various investors, including Petrichor, and has received breakthrough therapy designation for its drug candidate AURN001.
#Biotechnology